Studies Published in The Lancet Show Roflumilast Improves Lung Function and Reduces Exacerbations
Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
Original Source of Studies Published in The Lancet Show Roflumilast Improves Lung Function and Reduces Exacerbations
